Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide.

Slides:

Advertisements

Similar presentations

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.

Advertisements

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation Patrick.

Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Retrospective.

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation Patricia M. Sheean,

The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates Ian Nivison-Smith, Judy M. Simpson, Anthony.

Prognostic Importance of Functional Capacity for Pre-Transplant Risk Assessment Among Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

How to Treat MDS without Stem Cell Transplantation

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Low Dose Unfractionated Heparin (UFH) Prophylaxis Is a Feasible Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome (SOS) after Myeloablative.

Utility of Comorbidity Assessment in Predicting Transplantation-Related Toxicity Following Autologous Hematopoietic Stem Cell Transplantation for Multiple.

Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant Maria Gil-Cupello, BA, Gunjan.

Vaccination of Children following Allogeneic Stem Cell Transplantation

Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation Joseph H. Antin, Eva C. Guinan,

Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic.

A Response Adapted Approach to Induction Treatment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Gunjan L. Shah,

Systematic Anti-Mold Prophylaxis Results in Very Low Incidence of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Immune-Mediated Hemolytic Anemia (IMHA) and Immune Thrombocytopenia (ITP) after Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation

Combining the Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Provides a Comprehensive Prognostic Model for.

CMV Seropositivity and Viremia Drive T-Cell Reconstitution after CD34-Selected Allogeneic HCT Christina Cho, Patrick Hilden, Ioannis Politikos, Taylor.

Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis.

Gain of Chromosome 1q Portends Worse Prognosis in Multiple Myeloma Patients Treated with Novel Agent Based Induction Regimens Even after Autologous Transplantation

Sabina Kersting, Leo F. Verdonck

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic.

Caroline F. Morrison, Donna M

Recipient CMV Seropositivity & Viremia is Associated with the Development of Cord Blood (CB) Derived CD8 + Effectors & Effector Memory Cells in Adults.

Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant Maria Gil-Cupello, BA, Gunjan.

The Role of Post-Remission Chemotherapy before T-Cell Depleted Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia in First Complete Remission

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

Early Toxicities Associated with Radiation Based Conditioning for Relapsed/Refractory Hodgkin Lymphoma Patients Undergoing High Dose Therapy and Autologous.

Pharmacokinetics and Toxicities after Evomela® (Propylene Glycol Free Melphalan) with Hematopoietic Stem Cell Transplant (HCT) for Multiple Myeloma (MM),

More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes Without Adding Serious Toxicity When Compared to Fludarabine/Melphalan.

Biology of Blood and Marrow Transplantation

Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies Gunjan L. Shah, Leyla Shune,

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation Vijaya.

Biology of Blood and Marrow Transplantation

Graft-Versus Host Disease (GVHD Status and Severity Mediate Late Effects of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in a 1-Year Landmark.

Long-Term Prognosis Among 1-Year Survivors of Ex Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation: A Landmark Analysis Christina.

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

Disease Progression is Main Barrier to Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in Patients with Newly Diagnosed and Relapsed Acute Leukemia

Members of the Intestinal Microbiota Are Associated with Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Jonathan U. Peled, MD, PhD,

Kamal Kant Singh Abbi, Junting Zheng, Sean M

David J. Chung, MD, PhD, Katherine B. Pronschinske, Justin A

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Dharshan Sivaraj, Michael.

CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma Eric Smith, Sean M. Devlin, Satyajit.

Biology of Blood and Marrow Transplantation

The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group Amber B. Clemmons,

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic Syndromes Bartlomiej M. Getta, Ashwin Kishtagari,

Incidence of Adrenal Insufficiency in Patients with Multiple Myeloma during High Dose Chemotherapy and Autologous Stem Cell Transplant Ahmad Hatem Mattour,

Pauline Damien, David S. Allan

Comparison of T Cell Subset Recovery after Cord Blood and CD34-Selected Pbsc Transplantation Christina Cho, Ioannis Politikos, Patrick Hilden, Taylor.

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation Patrick.

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation Mohammed M. Elayan, Justin G.

What is quality in a transplant program?

CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50.

Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving.

Blood and Marrow Transplant Handbook

Bernard Maybury, Gordon Cook, Guy Pratt, Kwee Yong, Karthik Ramasamy

Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.

Cytomegalovirus Infection after CD34+-Selected Hematopoietic Cell Transplantation Yao-Ting Huang, Dionysios Neofytos, Julia Foldi, Seong Jin Kim, Molly.

Mammen Chandy Biology of Blood and Marrow Transplantation

Early Fluid Overload is a Serious Toxicity Associated with an Increased Risk of Non- Relapse Mortality after Ex-Vivo CD34-Selected Allogeneic Hematopoietic.

Mary Eapen Biology of Blood and Marrow Transplantation

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma Luciano J. Costa, Jia-Xing Huang, Parameswaran.

Presentation transcript:

Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Meighan Palazzo, Gunjan L. Shah, Olivia Copelan, Kenneth Seier, Sean M. Devlin, Molly Maloy, Sheila Kenny, Hani Hassoun, Neha S. Korde, Nikoletta Lendvai, Alexander M. Lesokhin, Sham Mailankody, David J. Chung, Guenther Koehne, C. Ola Landgren, Heather Landau, Sergio A. Giralt, Miguel-Angel Perales Biology of Blood and Marrow Transplantation Volume 24, Issue 4, Pages 871-876 (April 2018) DOI: 10.1016/j.bbmt.2017.12.795 Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Response by vaccine subtype. Biology of Blood and Marrow Transplantation 2018 24, 871-876DOI: (10.1016/j.bbmt.2017.12.795) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Percentage of patients on lenalidomide maintenance versus not on LM who responded (excluding patients who retained immunity or were not evaluable). Biology of Blood and Marrow Transplantation 2018 24, 871-876DOI: (10.1016/j.bbmt.2017.12.795) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions